AstraZeneca signs $2 billion agreement with Quell to develop cell
therapies
Send a link to a friend
 [June 09, 2023]
(Reuters) - AstraZeneca said on Friday it had signed an agreement
with Quell Therapeutics potentially worth more than $2 billion to
develop cell therapies that could cure autoimmune diseases.
The agreement includes developing, manufacturing and commercialising
cell therapies that have the potential to be curative in type 1 diabetes
and inflammatory bowel disease indications, the drugmaker said in a
statement.
UK-based Quell will receive $85 million upfront from AstraZeneca, and is
also eligible to receive over $2 billion for further development and
commercialisation milestones, the company added.
[to top of second column]
|
Test tubes are seen in front of a
displayed AstraZeneca logo in this illustration taken, May 21, 2021.
REUTERS/Dado Ruvic/Illustration
 (Reporting by Radhika Anilkumar in
Bengaluru; Editing by Rashmi Aich)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
